[CAS NO. 1402601-82-4]  TUG-770

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1402601-82-4]

Catalog
HY-15697
Brand
MCE
CAS
1402601-82-4

DESCRIPTION [1402601-82-4]

Overview

MDLMFCD26142679
Molecular Weight307.32
Molecular FormulaC19H14FNO2
SMILESFC1=C(CCC(O)=O)C=CC(C#CC2=C(CC#N)C=CC=C2)=C1

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE


Summary

TUG-770 is a potent, selective and orally active GPR40/FFA1 agonist with an EC 50 of 6 nM for human FFA1 . TUG-770 shows a high selectivity for FFA1 over FFA2, FFA3, FFA4, PPARγ , other receptors, transporters, and enzymes. TUG-770 can be uesd for type 2 diabetes research [1] .


IC50 & Target

EC50: 6 nM (Human GPR40/FFA1) [1]


In Vitro

TUG-770 (Compound 22) displays excellent physicochemical and in vitro ADME properties, with good aqueous solubility, good chemical stability, low lipophilicity, and decreased plasma protein binding (PPB). TUG-770 shows excellent stability toward human liver microsomes (HLM), and good permeability in the Caco-2 cell assay [1] .
TUG-770 exhibits lower potency on the rodent orthologs (mFFA1, pEC 50 = 6.83; rFFA1, pEC 50 = 6.49) [1] .
In the rat INS-1E cell line, TUG-770 significantly increases insulin secretion (10.75% of total content with 10 μM 22 vs 8.74 with vehicle) at high glucose concentration (12.4 mM) and, no effect (4.14% of total content with 10 μM 22 vs 4.02 with vehicle) at low glucose concentration (2.8 mM) [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

TUG-770 (Compound 22; 20 mg/kg; oral administration; daily; for 28 days) treatment significantly improves glucose tolerance, and has no effect on food intake, body weight, body composition or plasma leptin concentration. TUG-770 also significantly improves the insulin sensitivity index (plasma glucose x plasma insulin) [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C56B1/6 male mice (5-6 weeks of age) fed on the 60% fat diet D12492 [1]
Dosage: 20 mg/kg
Administration: Oral administration; daily; for 28 days
Result: Significantly improved glucose tolerance.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 325.39 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.2539 mL 16.2697 mL 32.5394 mL
5 mM 0.6508 mL 3.2539 mL 6.5079 mL
10 mM 0.3254 mL 1.6270 mL 3.2539 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (8.13 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (8.13 mM); Clear solution

* All of the co-solvents are available by MCE.